Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Drug Discovery
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 319161
Licensed Product means all finished pharmaceutical formulations containing the Compound in any dosage form for human use.
Licensor is engaged in the development of novel pharmaceuticals for central nervous system indications and has licensed from Rhone-Poulenc Rorer, S.A. (RPR) certain rights to the Compound.
Pagoclone is an anxiolytic agent from the cyclopyrrolone family, related to better-known drugs such as the sleeping medication zopiclone. Drug pagoclone is for the treatment of panic and generalized anxiety disorders.
IPSCIO Record ID: 319181
Compound means singly and collectively 2-(7-chloro-1, 8-naphtyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone, the (+) enantiomer of which is known as RP62955 or pagoclone.
Product means any pharmaceutical preparation in final form, or, where the context so indicates, the form under development, containing the Compound as a primary active therapeutic ingredient, which requires a prescription from a physician or other health care professional for use in the Territory.
IPSCIO Record ID: 369293
5,874,418 – Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
6,046,177 – Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
6,133,248 – Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
Licensed Product means (a) a Compound combined with or formulated using Captisol for ultimate use in humans in a dosage form/formulation, or (b) a pharmaceutical composition that includes a Compound and that is developed with the assistance of or incorporates any then-confidential component of the Captisol Data Package.
Compound means the proprietary Licensee isoflavone-based drug compound known as ME-143 (also known as NV-143) or the proprietary Licensee mitochondrial inhibitor drug compound known as ME-344, or any derivative, homolog, or analog of ME-143 or ME-344 or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing.
Captisol Related Compound means Captisol or any derivative, homolog analog of Captisol or any isomer, salt, hydrate, solvate, amide, ester, metabolite or product of any of the foregoing, including without limitation sulfobutylether g(gamma) cyclodextrin sodium salt.
Licensed Product Family means one or more Licensed Products which are based on the same Compound(s) (or any isomers, salts, hydrates, solvates, amides, esters, metabolites, or prodrugs of the foregoing), irrespective of whether such Licensed Products contain different dosage forms, proportions or formulations of such Compound(s), utilize different inactive ingredients and/or are marketed for different indications. Notwithstanding the foregoing, a Licensed Product based on a Compound shall be deemed to be in a distinct Licensed Product Family from a Licensed Product based on the combination of the same relevant Compound with any other active pharmaceutical ingredient. As such, if Licensee develops one Licensed Product with ME-344 as the sole active ingredient with Captisol and also develops another Licensed Product with ME-344 in combination with another active ingredient with Captisol, then two distinct sets of milestone payments shall be potentially due under this Agreement, one for each of such two distinct Licensed Products.
Captisol is for use with the Licensee’s isoflavone-based drug compounds.
ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. In preclinical studies, ME-344 has been shown to cause cell death in multiple human tumor cell lines, including ovarian cancer stem cells, by interfering with mitochondrial energy generation.
Field means the entire field of prevention, diagnosis and treatment of all human and animal diseases and disorders with the exceptions of (i) ocular treatment of any disease or condition with a formulation including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration.
IPSCIO Record ID: 336365
For Research and Manufacturing License Outside the Territory, Licensor grants a non-exclusive license, with the right to sublicense, under the Licensor Patents that cover outside of the Territory and the Licensor Know-How and Licensors rights under the Joint Inventions and Joint Patents, to research, develop and manufacture the Licensed Molecules and Products outside the Territory solely for the purpose of advancing the research, development and commercialization of the Licensed Molecules and Products in the Field in the Territory.
Licensed Molecules shall mean any and all compounds that arc claimed or covered by an Licensor Patent, including, but not limited to PCAP-872, PCAP-831, PCAP-924 and PCAP-130, and the salts, metabolites and pro-drugs of such compounds.
Product shall mean a pharmaceutical product containing at least one Licensed Molecule, including all dosage forms, formulations, line extensions and modes of administration thereof.
The patents include
– Amino substituted diary [a,d.] Cycloheptene analogs as muscarinic agonists and methods of treatment of Neuropsychiatric disorders,
– Use of N-Desmethylclozapine and related compounds as dopamine stabilizing agents, and,
– Prodrugs of muscarinic agonists and methods of treatment of Neuropsychiatric disorders.
IPSCIO Record ID: 239024
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.
IPSCIO Record ID: 315858
CNS means the human central nervous system.
Vaccine Product means a Vaccine that derives from a Validated Vaccine Candidate.
Validated Vaccine Candidate means a biological molecule that (a) is (i) a Protein encoded by a Candidate Gene, (ii) another Protein, the identification or development of which is based upon the identification of a Candidate Gene, or (iii) a Gene Therapy Drug, the identification or development of which is based upon the identification of a Candidate Gene, and (b) is suitable for development as a Vaccine. The determination that such biological molecule has achieved the status of a Validated Vaccine Candidate shall be made in good faith by Vaccine Management Team on the basis of objective criteria to be set forth in the Research Program Plan with respect to such biological molecule.
Modified Drug means a compound, the identification of which is based upon another compound that (a) other than through the use of Licensor Program Know-How or Licensor Program Patent Rights, prior to or outside of the Licensor Research Program, is known to Licensee to have pharmacological properties of relevance to its development as a therapeutic product in the CNS Disorders Field, and (b) is modified by Licensee or Licensor through the use of Licensor Program Know-How or Licensor Program Patent Rights to prove its therapeutic properties (but not merely to characterize the compound) for use in the CNS Disorders Field.
License Program Patent Right(s) means a Patent Right that relates to Licensor Program Know-How.
Licensor Program Know-How means Know-How, exclusive of Joint Program Know-How, owned or controlled by Licensor which is reasonably necessary in order to discover Candidate Genes, Validated Targets and Validated Vaccine Candidates and to discover, develop, make, use, sell or seek approval to market Products for medical indications in the Core Field, and which (a) is in Licensor possession on the Effective Date, or (b) Licensor develops in the course of the Licensor Research Program, or (c) Licensor acquires in the course of the Licensor Research Program and to which Licensor has the right to grant licenses or sublicenses without violating the terms of any agreement or other arrangement with a third party, provided, however, that Licensor Program Know-How shall not include (i) generalized methods for conducting genomic research and characterizing the function of genes, including without limitation Licensor Rade Technology and other MTPT (as those terms are defined in the TPT Access and License Agreement), and (ii) phenotypic and genotypic information and biological samples relating to human materials acquired or otherwise accessed by Licensor and used in genetic analysis in the Licensor Research Program (other than such information and samples which Licensee participates in obtaining, including information and samples specifically obtained from the Licensee patient base).
Core Field means the disorders set forth, as may be modified from time to time.
Psychosis including without limitation Schizophrenia and Drug-induced psychosis.
Affective Disorders including without limitation Bipolar (manic) depression, generalized (unipolar, major, common) depression hyperthymia/dysthymia, obsessive compulsive disorders, generalized anxiety, panic disorders, serotonin disorders syndrome, post-traumatic stress disorders, circadian rhythm disorders and pre-menstrual syndrome.
Expansion Field means the disorders set forth, as may be modified from time to time.
ALS, Childhood Autism, Conduct Disorders, Disorders of Vision, Hearing Loss, Hereditary Ataxias, Headache/Migraine, Hereditary Neuropathies, Huntingtons Disease, Learning Disorders, Chronic Fatique Syndrome, Pain, Parkinsons Disease and Sleep Disorders.
Reserve Field means the disorders set forth, as may be modified from time to time.
Dementias, Seizure Disorders, CNS Stroke/Trauma and Substance Abuse.
